EQS-Adhoc: Vitruvia Medical AG: Issue of 6.00% Convertibel Bond 2022-2025
EQS-Ad-hoc: Vitruvia Medical AG / Key word(s): Financing
Vitruvia Medical AG: Issue of 6.00% Convertibel Bond 2022-2025
26-Nov-2022 / 16:43 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Convertible bond Vitruvia Medical AG ("Private Placement") 6.00% 2022-2025
By resolution of the Board of Directors, Vitruvia Medical AG has resolved to issue a convertible bond ("Private Placement") of CHF 2.2 million at an interest rate of 6.00% p.a. and a term of 3 years. The issue price is set at 100% and the conversion price is EUR 2.50 and is convertible into registered shares of Vitruvia Medical AG.
The funds will be used to finance existing projects (LT technologies GmbH & Co. KG), acquisitions (rebuilding of the investment portfolio) and general corporate financing.
Anglikon, 26 November 2022
Vitruvia Medical Ltd.
Board of directors
26-Nov-2022 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.eqs-news.com
|
Language: |
English |
Company: |
Vitruvia Medical AG |
|
Kesselackerstr. 18 |
|
5611 Anglikon |
|
Switzerland |
Phone: |
+41 44 915 33 78 |
E-mail: |
[email protected] |
Internet: |
www.vitruvia-med.com |
ISIN: |
CH0461931419 |
WKN: |
A2PDWF |
Listed: |
Regulated Unofficial Market in Munich |
EQS News ID: |
1498163 |
|
End of Announcement |
EQS News Service |
1498163 26-Nov-2022 CET/CEST
Die wichtigsten Finanzdaten auf einen Blick
|
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
2023 |
Umsatzerlöse1 |
0,00 |
0,00 |
0,00 |
5,60 |
1,97 |
1,42 |
1,75 |
EBITDA1,2 |
0,00 |
0,00 |
0,00 |
-0,96 |
-0,75 |
-0,91 |
0,06 |
EBITDA-Marge3 |
0,00 |
0,00 |
0,00 |
-17,14 |
-38,07 |
-64,08 |
|
EBIT1,4 |
0,00 |
0,00 |
0,00 |
-1,31 |
-7,69 |
-1,24 |
-0,37 |
EBIT-Marge5 |
0,00 |
0,00 |
0,00 |
-23,39 |
-390,36 |
-87,32 |
-21,14 |
Jahresüberschuss1 |
0,00 |
0,00 |
0,00 |
-1,54 |
-7,71 |
-1,48 |
-0,54 |
Netto-Marge6 |
0,00 |
0,00 |
0,00 |
-27,50 |
-391,37 |
-104,23 |
-30,86 |
Cashflow1,7 |
0,00 |
0,00 |
0,00 |
-0,21 |
-0,78 |
-0,67 |
-0,10 |
Ergebnis je Aktie8 |
0,00 |
0,00 |
0,00 |
-0,85 |
-4,19 |
-0,59 |
-0,21 |
Dividende8 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
0,00 |
Quelle: boersengefluester.de und Firmenangaben
Geschäftsbericht 2023 - Kostenfrei herunterladen.
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de
Wirtschaftsprüfer: BDO
|
INVESTOR-INFORMATIONEN |
©boersengefluester.de |
Vitruvia Medical |
WKN |
Kurs in € |
Einschätzung |
Börsenwert in Mio. € |
A2PDWF |
0,300 |
|
0,75 |
KGV 2025e |
KGV 10Y-Ø |
BGFL-Ratio |
Shiller-KGV |
0,00 |
0,00 |
0,00 |
-0,12 |
KBV |
KCV |
KUV |
EV/EBITDA |
-1,51 |
- |
0,43 |
32,63 |
Dividende '22 in € |
Dividende '23 in € |
Div.-Rendite '23 in % |
Hauptversammlung |
0,00 |
0,00 |
0,00 |
24.06.2024 |
Q1-Zahlen |
Q2-Zahlen |
Q3-Zahlen |
Bilanz-PK |
|
30.09.2024 |
|
01.05.2024 |
Abstand 60Tage-Linie |
Abstand 200Tage-Linie |
Performance YtD |
Performance 52 Wochen |
-28,06% |
-56,65% |
-75,00% |
-72,73% |
|
|